Dual PET Imaging with [68Ga]Ga-DOTA-TOC and [18F]FDG to Localize Neuroendocrine Tumors of Unknown Origin
Current Oncology · 2025
DOI: 10.3390/curroncol32090497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Ali Zaidi und 10 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer, Vancouver, BC V5Z 4E6, Canada. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Fluorodeoxyglucose F18, Octreotide, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BC Cancer Foundation, philanthropic research funding from the BC Cancer Foundation.
Abstract (Originalsprache)
Neuroendocrine tumors of unknown primary (CUP-NET) present a diagnostic challenge when conventional imaging fails to localize the primary tumor. This study aimed to evaluate the diagnostic value of concurrent [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT imaging in localizing primary tumors in patients with histologically confirmed CUP-NET. Thirty-four patients underwent both imaging modalities as part of a prospective imaging protocol after negative conventional imaging or [111In]In-octreotide scintigraphy. Primary tumor detection rates were assessed, and imaging characteristics compared between the two modalities. The overall localization rate was 58.9% (20/34). Of these, 90% (18/20) of primary tumors were identified solely by [68Ga]Ga-DOTA-TOC PET/CT, with the remaining two visualized by both modalities. [18F]FDG PET/CT did not independently localize any primary tumors. Identified primaries were limited to grade 1 (60%) or grade 2 (40%) tumors, predominantly in the small intestine (95%). Among localized cases, 45% (9/20) underwent surgical resection and 15% (3/20) became eligible for peptide receptor radionuclide therapy. [68Ga]Ga-DOTA-TOC PET/CT demonstrated superior detection of metastatic lesions compared to [18F]FDG PET/CT (97.1% vs. 70.6%, p = 0.006). No significant survival differences were observed between patients with localized versus non-localized primaries. These findings support the value of [68Ga]Ga-DOTA-TOC PET/CT for identifying primary tumors in CUP-NET. Further research is warranted to explore the role of [18F]FDG PET/CT in high-grade NETs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BC Cancer, Vancouver, BC V5Z 4E6, Canada.
- Vancouver General Hospital, Vancouver, BC V5Z 1N1, Canada.
- Department of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
ORCID-Profile: Ali Zaidi, Ingrid Bloise, Heather C Stuart, François Bénard, Jonathan M Loree
Förderung
- BC Cancer Foundation
- philanthropic research funding from the BC Cancer Foundation
Zitieren
APA
Zaidi, A., Ravi, P., Bloise, I., Harsini, S., Stuart, H. C., Kennecke, H. F., Alberts, I., Bénard, F., Wilson, D., Martineau, P., & Loree, J. M. (2025). Dual PET Imaging with [68Ga]Ga-DOTA-TOC and [18F]FDG to Localize Neuroendocrine Tumors of Unknown Origin. Current Oncology. https://doi.org/10.3390/curroncol32090497
Vancouver
Zaidi A, Ravi P, Bloise I, Harsini S, Stuart HC, Kennecke HF, et al. Dual PET Imaging with [68Ga]Ga-DOTA-TOC and [18F]FDG to Localize Neuroendocrine Tumors of Unknown Origin. Current Oncology. 2025. doi:10.3390/curroncol32090497
BibTeX
@article{Zaidi2025,
author = {Zaidi, Ali and Ravi, Pavithraa and Bloise, Ingrid and Harsini, Sara and Stuart, Heather C and Kennecke, Hagen F and Alberts, Ian and Bénard, François and Wilson, Don and Martineau, Patrick and Loree, Jonathan M},
title = {Dual PET Imaging with [68Ga]Ga-DOTA-TOC and [18F]FDG to Localize Neuroendocrine Tumors of Unknown Origin},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32090497}
}
EUVIMED